NRx Pharmaceuticals, Inc. (NRXP) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
NRx Pharmaceuticals, Inc.
Address
1201 Orange Street
Wilmington, DE 19801
United States of America (the)
Phone
484 254 6134
Website
Sector
Healthcare
Industry
Biotechnology
Employees
29
First IPO Date
December 04, 2017
Key Executives
| Name | Title | Pay | Year Born |
| Jonathan C. Javitt | Co-Founder, Chairman & CEO | 846,774 | 1957 |
| Dennis K. McBride | Chief Strategy Officer & Director | 38,462 | 1954 |
| Riccardo Panicucci | Chief Manufacturing & Technology Officer | 240,000 | 1962 |
| Michael S. Abrams | CFO & Treasurer | 363,083 | 1970 |
| Hervé Perron | Chief Scientist | 0 | 1959 |
| Joshua C. Brown | Chief Medical Innovation Officer | 0 | N/A |
| Philip T. Lavin | Chief Methodologist | 0 | 1947 |
| Glenn Tyson | Chief Commercial Officer | 0 | N/A |
| Joseph Casper | Chief Operating Officer | 0 | 1951 |
| Michael Taylor | Chief Development Officer & Director | 0 | 1975 |
| Suzanne Messere | Investor Relations | 0 | N/A |
Description
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
